Amylyx Pharmaceuticals Inc. will charge at least $158,000 annually for its newly approved drug to treat amyotrophic lateral sclerosis, or ALS, the company said Friday.
The drug, called Relyvrio, was approved by the Food and Drug Administration late Thursday after some staff had raised questions about whether there was enough evidence to show the drug works. It is the first new treatment in five years for ALS, which is also known as Lou Gehrig’s disease, and promises to slow its progression and extend the lives of patients by several months.
